drugset
drugset / Trial / NCT04448964

A Study of JNJ-70033093 in Healthy Participants

NCT04448964 ↗

Phase 1 Completed 24 enrolled Janssen Research & Development, LLC Bristol-Myers Squibb · collab
RandomizedCrossoverOpen-labelOther

Summary

The purpose of this study is to evaluate the pharmacokinetics (PK) and relative bioavailability of a single dose of JNJ-70033093 spray dried dispersion (SDD) tablets compared with JNJ-70033093 SDD granule capsules in healthy participants under fasting conditions in Part 1 and 2 and to assess the effect of food on the bioavailability of a single dose of JNJ-70033093 SDD tablets in Part 1.

Timeline

Start
2020-06-26
Primary completion
2020-11-14
Completion
2020-11-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Milvexian Small molecule — Oral

Indications

No indication recorded.